Allogene Therapeutics, Inc. Form 8-K Summary
Reporting date: October 6, 2022. The filing reports clinical-development and manufacturing updates under Item 8.01, rather than quarterly financial results.
Business Context and Reporting Period
Allogene is developing allogeneic CAR T-cell therapies. The company announced initiation of the Phase 2 ALPHA2 trial of ALLO-501A in patients with relapsed/refractory large B-cell lymphoma (r/r LBCL) and plans to initiate the EXPAND trial evaluating the contribution of ALLO-647 to the lymphodepletion regimen.
Key Financial and Operating Metrics
- The filing does not provide revenue, profit or loss, cash flow, margins, debt, liquidity, or other financial statement metrics.
- ALPHA2 is expected to enroll approximately 100 patients who have received at least two prior lines of therapy and no prior anti-CD19 therapy, including CAR T therapy.
- ALPHA2 will evaluate a single 120 million CAR+ cell dose of ALLO-501A. The planned lymphodepletion regimen includes fludarabine, cyclophosphamide, and 90 mg of ALLO-647.
- EXPAND is expected to enroll approximately 70 patients and randomize them between fludarabine/cyclophosphamide alone and the same regimen plus ALLO-647.
- The primary endpoint of ALPHA2 is objective response rate. EXPAND is intended to evaluate ALLO-647’s safety and contribution to the overall treatment benefit.
Material Changes Versus the Prior Comparable Period
- The company moved ALLO-501A into Phase 2 development through the ALPHA2 trial.
- Allogene selected the Alloy manufacturing process following a review of its Phase 1 program and intends to use it in the ALPHA2 and EXPAND trials.
- Phase 2 will initially use previously manufactured product from a prior contract manufacturing organization, with an intended transition to product manufactured at Allogene’s Cell Forge 1 facility during the trials.
- The company added a risk factor concerning manufacturing, regulatory, enrollment, and clinical-outcome challenges that could delay or prevent development and approval.
Guidance, Outlook, Risks, and Unusual Items
- Allogene expects to provide an update on its CD19 program toward the end of 2022, including longer-term follow-up from the Phase 1 ALPHA and ALPHA2 trials and patients treated using the Alloy process.
- Subject to favorable results and FDA discussions, the company plans to seek approval of ALLO-501A and ALLO-647 based on ALPHA2 and EXPAND.
- FDA clearance was received to use newly manufactured product from Cell Forge 1 that was not produced using the Alloy process; implementation of Alloy at Cell Forge 1 is ongoing.
- Manufacturing continuity, CMO capacity, transition of Alloy to Cell Forge 1, FDA review, patient enrollment, and clinical outcomes could cause increased costs, delays, additional data requirements, or additional trials.
- Enrollment may be difficult because the trials exclude certain disease characteristics and patients previously treated with autologous CAR T therapies, which are becoming more widely used.
- Phase 2 results may not replicate Phase 1 results, which were based on a limited number of patients. The FDA could require longer follow-up, additional clinical data, or additional studies before accepting a Biologics License Application.
Investor Verification Checklist
- Verify the timing and pace of enrollment in ALPHA2 and initiation of EXPAND.
- Verify whether the Alloy manufacturing process is successfully transferred to and validated at Cell Forge 1.
- Review subsequent FDA feedback regarding trial design, manufacturing, and potential registrational pathways.
- Compare longer-term Phase 1 and Phase 2 efficacy and safety data with the company’s expectations.
- Assess later filings for cash runway, trial costs, liquidity, and any financing or manufacturing-related obligations, which are not provided in this 8-K.